Polen: BD Aiming For Higher Growth Spaces And More Tuck-Ins
BD stressed the continued pursuit of an innovation-driven growth strategy as it announced fiscal 2021 sales of $20bn spurred by its pandemic response effort.
You may also be interested in...
Becton Dickinson has formally completed the planned spin-off of its diabetes business within the timeframe it projected about a year ago. The new company, called embecta, is one of the largest producers of diabetes injection devices.
BD believes the independent new company will create shareholder value and is part of the BD 2025 growth strategy.
After a runaway 2021 and a strong if bumpy first quarter of 2022, all health care product sectors underwent an investment dip in the second quarter, says Silicon Valley Bank. Healthtech in Europe remained a stand-out performer.